|Trade names||Pill form is generic and available under many brand names; transdermal patch is called Emsam|
|Oral, transdermal, buccal|
|Bioavailability||4.4% (oral, fasted), 20% (oral, after food), 73% (patch)|
|Metabolism||Extensive in liver|
|Metabolites||N-desmethylselegiline, L-amphetamine and L-methamphetamine|
|Biological half-life||10 hours (oral), 18–25 hours (transdermal)|
|Excretion||Urine (main route)|
|Chemical and physical data|
|Molar mass||187.281 g/mol|
|3D model (Jmol)|
Selegiline, also known as L-deprenyl, is a substituted phenethylamine. At normal clinical doses, it is a selective irreversible MAO-B inhibitor. In larger doses it loses its specificity and also inhibits MAO-A. It is available in pill form under many brand names and is used to reduce symptoms in early-stage Parkinson's disease. A transdermal patch (brand name, Emsam) is used to treat depression.
- 1 Medical uses
- 2 Adverse effects
- 3 Pharmacology
- 4 Chemistry
- 5 History
- 6 Research
- 7 Society and culture
- 8 See also
- 9 References
For all human uses and all forms, selegiline is Pregnancy Category C, meaning that caution is in order because studies in pregnant laboratory animals have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but that the drug's potential benefits may nonetheless warrant use of the drug in some pregnant women.
Selegiline delays the time point when the L-DOPA (levodopa) treatment becomes necessary from about 11 months to about 18 months after diagnosis, which is beneficial despite not being definitive evidence of neuroprotection. The rationale for adding selegiline to levodopa is to decrease the required dose of levodopa and thus reduce the motor complications of levodopa therapy.
A quantitative review published in 2015 found that for the pooled results of the pivotal trials, the number needed to treat (a sign of effect size, so a low number is better) for the patch for symptom reduction was 11, and for remission, was 9. The number needed to harm (inverse of the NNT, a high number here is better) ranged from 387 for sexual side effects to 7 for application site reaction. With regard to the likelihood to be helped or harmed (LHH), the analysis showed that the selegiline patch was 3.6 times as likely to lead to a remission vs. a discontinuation due to side effects; the LHH for remission vs. incidence of insomnia was 2.1; the LHH for remission vs. discontinuation due to insomnia was 32.7. The LHH for remission vs insomnia and sexual dysfunction were both very low.
Selegiline (brand name Anipryl) is also used (at extremely high dosages relative to humans) in veterinary medicine to treat the symptoms of Cushing's disease and cognitive dysfunction (Canine Cognitive Dysfunction) in dogs.
Side effects of the pill form include, in decreasing order of frequency, nausea, hallucinations, confusion, depression, loss of balance, insomnia, increased involuntary movements, agitation, arrhythmia, slow heart rate, delusions, hypertension, new or increased angina pectoris, and syncope.
The main side effects of the patch form for depression included application site reactions, insomnia, diarrhea, and sore throat.
Both forms of the drug carry strong warnings against combining selegiline with drugs that could produce serotonin syndrome, which include SSRIs and the cough medicine, dextromethorphan. Selegiline in combination with the opioid analgesic pethidine is not recommended as it can lead to severe adverse effects. Several other synthetic opioids such as tramadol and methadone, dextromethorphan, and various triptans are contraindicated due to potential for serotonin syndrome.
Both forms of the drug carry warnings about food restrictions, to avoid hypertensive crisis that are associated with MAO inhibitors. The patch form of the drug was created in part to overcome the issues with food restrictions: the clinical trials did not include food restrictions, and no hypertensive crisis during the course of them. Additionally, in post-marketing surveillance from April 2006 to October 2010, only 13 self-reports of possible hypertensive events or hypertension were made out of 29,141 exposures to the drug, and none were accompanied by objective clinical data. The lowest dose of the patch method of delivery, 6 mg/24 hours, does not require any dietary restrictions. Higher doses of the patch and oral formulations, whether in combination with the older non-selective MAOIs or in combination with the reversible MAO-A inhibitor moclobemide, require a low tyramine diet.
Pharmacokinetics of the pill form
Selegiline's oral bioavailability is drastically increased in females taking oral contraceptives (10- to 20-fold). This could lead to loss of MAO-B selectivity, with inhibition of both MAO-A and MAO-B, which would make patients susceptible to the usual risks of unselective MAOIs such as tyramine-induced hypertensive crisis and serotonin toxicity when combined with serotonergics such as SSRIs.
Pharmacokinetics of the patch form
Following application of the patch to humans, 25% to 30% of the selegiline content on average is delivered systemically over 24 hours (range approximately 10% to 40%). Transdermal dosing results in significantly higher exposure to selegiline with significantly lower exposure for all metabolites when compared to oral dosing, due to extensive first-pass metabolism for the pill form and low first-pass metabolism for the patch form. The site of application is not a significant factor in how the drug is distributed. In humans, selegiline does not accumulate in the skin nor is it metabolized in the skin.
N-Desmethylselegiline may have neuroprotective antiapoptotic properties. A large multicenter study suggests a decrease in the disease progression of Parkinsonism but may have reflected other symptomatic response. Desmethylselegiline is metabolized by CYP2C19.
Levoamphetamine and levomethamphetamine
Selegiline is partly metabolized to levomethamphetamine (L-methamphetamine), one of the two enantiomers of methamphetamine, in vivo. While these metabolites may contribute to the drug's ability to inhibit reuptake of the neurotransmitters dopamine and norepinephrine, they have also been associated with orthostatic hypotension and hallucinations in some people. A newer antiparkinson MAO-B inhibitor, rasagiline, metabolizes into 1(R)-aminoindan which has no amphetamine-like characteristics.
Selegiline belongs to a class of drugs called phenethylamines. Selegiline is an L-methamphetamine derivative with a propargyl group attached to the nitrogen atom. This detail is borrowed from pargyline, an older phenethylamine MAO-B inhibitor.
Following the discovery that the tuberculosis (TB) drug iproniazid elevated the mood of people taking it for TB, and the subsequent discovery that the effect was likely due to inhibition of MAO, many people and companies started trying to discover MAO inhibitors to use as antidepressants. Selegiline was discovered by Z. Ecseri at the Hungarian drug company, Chinoin (part of Sanofi since 1993), which they called E-250.:66–67 Chinoin received a patent on the drug in 1962 and the compound was first published in the scientific literature in English in 1965.:67 Work on the biology and effects of E-250 in animals and humans was conducted by a group led by József Knoll at Semmelweis University which was also in Budapest.:67
Deprenyl is a racemic compound, a mixture of two isomers called enantiomers. Further work determined that the levorotatory enantiomer was a more potent MAO-inhibitor, which was published in 1967, and subsequent work was done with the single enantiomer L-deprenyl.:67
In 1971, Knoll showed that selegiline selectively inhibits the B-isoform of monoamine oxidase (MAO-B) and proposed that it is unlikely to cause the infamous "cheese effect" (hypertensive crisis resulting from consuming foods containing tyramine) that occurs with non-selective MAO inhibitors. A few years later, two Parkinson's disease researchers based in Vienna, Peter Riederer and Walther Birkmayer, realized that selegiline could be useful in Parkinson's disease. One of their colleagues, Prof. Moussa B.H. Youdim, visited Knoll in Budapest and took selegiline from him to Vienna. In 1975, Birkmayer's group published the first paper on the effect of selegiline in Parkinson's disease.
In 1987 Somerset Pharmaceuticals in New Jersey, which had acquired the US rights to develop selegiline, filed a new drug application (NDA) with the FDA to market the drug for PD in the US. While the NDA was under review, Somerset was acquired in a joint venture by two generic drug companies, Mylan and Bolan Pharmaceuticals. Selegiline was approved for Parkinson's disease by the FDA in 1989.
In the 1990s, J. Alexander Bodkin at McLean Hospital, an affiliate of Harvard Medical School, began a collaboration with Somerset to develop delivery of selegiline via a transdermal patch in order to avoid the well known dietary restrictions of MAO inhibitors. Somerset obtained FDA approval to market the patch in 2006.
Society and culture
Due to the structural similarity to amphetamine, selegiline has been classified as a controlled substance in Japan and thus can only be obtained with a prescription or special government license. Amphetamine and methamphetamine are illegal in the country.
In E for Ecstasy (a book examining the uses of the street drug ecstasy in the UK) the writer, activist and ecstasy advocate Nicholas Saunders highlighted test results showing that certain consignments of the drug also contained selegiline. Consignments of ecstasy known as "Strawberry" contained what Saunders described as a "potentially dangerous combination of ketamine, ephedrine and selegiline," as did a consignment of "Sitting Duck" Ecstasy tablets.
In the US, selegiline is available by prescription but is not scheduled as a controlled substance.
- Drugs.com international listings for selegiline Page accessed Feb 7, 2016
- Selegiline oral label. Updated Dec 31, 2008
- Emsam label Last revised Sept 2014. Index page at FDA
- Riederer P, Lachenmayer L, Laux G (August 2004). "Clinical applications of MAO-inhibitors". Curr. Med. Chem. 11 (15): 2033–43. doi:10.2174/0929867043364775. PMID 15279566.
- Riederer P, Lachenmayer L (November 2003). "Selegiline's neuroprotective capacity revisited". J Neural Transm. 110 (11): 1273–8. doi:10.1007/s00702-003-0083-x. PMID 14628191.
- Ives NJ, Stowe RL, Marro J, et al. (September 2004). "Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients". BMJ. 329 (7466): 593. doi:10.1136/bmj.38184.606169.AE. PMC . PMID 15310558.
- Citrome L, Goldberg JF, Portland KB (Nov 2013). "Placing transdermal selegiline for major depressive disorder into clinical context: number needed to treat, number needed to harm, and likelihood to be helped or harmed". J Affect Disord. 151 (2): 409–17. doi:10.1016/j.jad.2013.06.027. PMID 23890583.
- Lundgren, Becky. "Canine Cognitive Dysfunction". Veterinary Partner. Retrieved April 8, 2011.
- "Cognitive Dysfunction Syndrome". Long Beach Animal Hospital. Retrieved April 8, 2011.
- "Anipryl consumer information". Drugs.com Vet. Retrieved April 3, 2011.
- Braddock JA, Church DB, Robertson ID (2004). "Selegiline Treatment of Canine Pituitary-Dependent Hyperadrenocorticism" (PDF). Australian Veterinary Journal. Retrieved April 8, 2011. (PDF)
- Friedman RA, Leon AC (2007). "Expanding the black box – depression, antidepressants, and the risk of suicide". N. Engl. J. Med. 356 (23): 2343–6. doi:10.1056/NEJMp078015. PMID 17485726.
- Heinonen EH, Myllylä V (July 1998). "Safety of selegiline (deprenyl) in the treatment of Parkinson's disease". Drug Saf. 19 (1): 11–22. doi:10.2165/00002018-199819010-00002. PMID 9673855.
- Csoti, Ilona; Storch, Alexander; Müller, Walter; Jost, Wolfgang H. (2012). "Drug interactions with selegiline versus rasagiline". Basal Ganglia. Monoamine oxidase B Inhibitors. 2 (4, Supplement): S27–S31. doi:10.1016/j.baga.2012.06.003.
- Gillman, P. K. (2005). "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity". British Journal of Anaesthesia. 95 (4): 434–441. doi:10.1093/bja/aei210. ISSN 0007-0912. PMID 16051647.
- Jessen, Lois; Kovalick, Lawrence J.; Azzaro, Albert J. (2017-04-22). "The Selegiline Transdermal System (Emsam)". Pharmacy and Therapeutics. 33 (4): 212–246. ISSN 1052-1372. PMC . PMID 19750165.
- Katzung, Bertram G. Basic & Clinical Pharmacology. 9th Edition. 2004. page 453. Lange Medical Books - McGraw Hill Publishers.
- Siu, E. C.; Tyndale, R. F. (2008). "Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice". Journal of Pharmacology and Experimental Therapeutics. 324 (3): 992–9. doi:10.1124/jpet.107.133900. PMID 18065502.
- Itzhak, Yossef (1994). Sigma Receptors. Academic press. p. 84. ISBN 978-0-12-376350-1.
- Stone, T. W. (1993). Acetylcholine, Sigma Receptors, CCK and Eicosanoids, Neurotoxins. Taylor & Francis. p. 124. ISBN 978-0-7484-0063-8.
- Barrett, Jeffrey S.; Szego, Peter; Rohatagi, Shashank; Morales, Richard J.; Dewitt, Kimberly E.; Rajewski, Gregory; Ireland, Joyce (1996). "Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males". Pharmaceutical Research. 13 (10): 1535–40. doi:10.1023/A:1016035730754. PMID 8899847.
- Laine, Kari; Anttila, Markku; Helminen, Antti; Karnani, Hari; Huupponen, Risto (2001). "Dose linearity study of selegiline pharmacokinetics after oral administration: Evidence for strong drug interaction with female sex steroids". British Journal of Clinical Pharmacology. 47 (3): 249–54. doi:10.1046/j.1365-2125.1999.00891.x. PMC . PMID 10215747.
- Taavitsainen, Paivi; Anttila, Markku; Nyman, Leena; Karnani, Hari; Salonen, Jarmo S.; Pelkonen, Olavi (2000). "Selegiline Metabolism and Cytochrome P450 Enzymes:In vitro Study in Human Liver Microsomes*". Pharmacology and Toxicology. 86 (5): 215–21. doi:10.1034/j.1600-0773.2000.d01-38.x. PMID 10862503.
- Engberg, G; Elebring, T; Nissbrandt, H (1991). "Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons". The Journal of Pharmacology and Experimental Therapeutics. 259 (2): 841–7. PMID 1658311.
- Lemke, Thomas L.; Williams, David A, eds. (2012). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. p. 434. ISBN 1609133455.
- Bar Am, Orit; Amit, Tamar; Youdim, Moussa B. H. (2004-01-30). "Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline". Neuroscience Letters. 355 (3): 169–172. doi:10.1016/j.neulet.2003.10.067. ISSN 0304-3940. PMID 14732458.
- Yasar, S.; Goldberg, J. P.; Goldberg, S. R. (1996-01-01). "Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research". Journal of Neural Transmission. Supplementum. 48: 61–73. ISSN 0303-6995. PMID 8988462.
- Chen JJ, Swope DM (2005). "Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease". J Clin Pharmacol. 45 (8): 878–94. doi:10.1177/0091270005277935. PMID 16027398.
- Romberg, R. W.; Needleman, S. B.; Snyder, J. J.; Greedan, A. (1995-11-01). "Methamphetamine and amphetamine derived from the metabolism of selegiline". Journal of Forensic Sciences. 40 (6): 1100–1102. ISSN 0022-1198. PMID 8522918.
- Miklya, Ildiko (13 March 2014). "The History of Selegiline/(-)-Deprenyl the First Selective Inhibitor of B-Type Monoamine Oxidase and The First Synthetic Catecholaminergic Activity Enhancer Substance". International Network for the History of Neuropsychopharmacology. Retrieved 7 January 2016.
- J. Knoll, E. Sanfai, DE 1568277 (1966).
- J. Hermann Nee Voeroes, Z. Ecsery, G. Sabo, L. Arvai, L. Nagi, O. Orban, E. Sanfai, U.S. Patent 4,564,706 (1986)
- B. Brunova, M. Ferenc, EP 344675 (1989)
- Fowler, Joanna S. (1977). "2-Methyl-3-butyn-2-ol as an acetylene precursor in the Mannich reaction. A new synthesis of suicide inactivators of monoamine oxidase". The Journal of Organic Chemistry. 42 (15): 2637–7. doi:10.1021/jo00435a026. PMID 874623.
- Staff, The Pharma Letter. Sept 20, 1993 Sanofi Extends Holding in Chinoin
- Kalman Magyar. The pharmacology of selegiline. Chapter 4 in Monoamine Oxidases and their Inhibitors. Volume 100 of International Review of Neurobiology. Eds Moussa Youdim, Peter Riederer. Academic Press, 2011. ISBN 9780123864680
- Knoll J, Ecseri Z, Kelemen K, Nievel J, Knoll B (May 1965). "Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer". Arch Int Pharmacodyn Ther. 155 (1): 154–64. PMID 4378644.
- Magyar K, Vizi ES, Ecseri Z, Knoll J (1967). "Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methyl-propinylamine (E-250)". Acta Physiol Acad Sci Hung. 32 (4): 377–87. PMID 5595908.
- Healy, David (2000). "The psychopharmacology of life and death. Interview with Joseph Knoll.". The Psychopharmacologists, Vol. III: Interviews. London: Arnold. pp. 81–110. ISBN 0-340-76110-5.
- Birkmayer W, Riederer P, Youdim MB, Linauer W (1975). "The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil". J. Neural Transm. 36 (3–4): 303–26. doi:10.1007/BF01253131. PMID 1172524.
- William J. Cromie (2002-11-07). "Bodkin is Patching up Depression". Harvard University Gazette. Retrieved 2007-09-08.
- John T. Seaman, John T. Landry. Mylan: 50 Years of Unconventional Success : Making Quality Medicine Affordable and Accessible. UPNE, 2012. ISBN 9781611682700. Page 50
- Frampton, JE; Plosker, GL (2007). "Selegiline transdermal system: in the treatment of major depressive disorder". Drugs. 67 (2): 257–67, discussion 266–7. doi:10.2165/00003495-200767020-00006. PMID 17284087.
- Mary Duffy for the New York Times. December 3, 2002 Patch Raises New Hope For Beating Depression
- Cascade EF, Kalali AH, Preskorn SH (Jun 2007). "Emsam: the first year". Psychiatry (Edgmont). 4 (6): 19–21. PMID 20711332.
- Akhondzadeh, Shahin; Tavakolian, Reza; Davari-Ashtiani, Rozita; Arabgol, Fariba; Amini, Homayoun (1 August 2003). "Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 27 (5): 841–845. doi:10.1016/S0278-5846(03)00117-9. ISSN 0278-5846. PMID 12921918.
- "Effectiveness of Selegiline in Treating Marijuana Dependent Individuals". ClinicalTrials.gov. National Institute on Drug Abuse. March 2005. Retrieved February 16, 2007.
- "Usefulness of Selegiline as an Aid to Quit Smoking". ClinicalTrials.gov. National Institute on Drug Abuse. July 2004. Retrieved February 16, 2007.
- Saunders, N., & Heron, L., (1993) E for Ecstasy (Paperback), N. Saunders, London. (ISBN 0950162884)[page needed]
- See:  for details online.